Science Translational Medicine Impact Factor

Do not reconstruct a year-by-year Science Translational Medicine trend from search snippets. The publisher page exposes the current two-year and five-year values, while third-party directories can lag or mix metric years. Use this verification sequence instead:

The current 15.6 JIF should therefore be cited as a current snapshot, not as proof of a long-term rise or decline unless the historical rows have been checked in the same JCR record.

It gives you a useful signal about how the journal is positioned.

• Science Translational Medicine is a recognized destination for work that links mechanistic insight to disease relevance.

• The journal has enough citation density that publication here carries meaningful visibility in translational circles.

• Readers expect papers to matter to both laboratory researchers and clinically minded audiences.

• The journal's influence is strong enough that authors often compare it with other ambitious translational targets rather than with routine specialist outlets.

That is the upside of the number. It confirms that this is a serious translational journal with real reach.

The field-normalized context matters. A JCI of 3.13 means the journal's recent citation impact is well above the category baseline after field differences are considered. The five-year JIF of 16.8 also runs slightly above the two-year value, so the current evidence does not depend only on an unusually short citation window. Those are journal-level signals, not manuscript-level promises.

For an author, the useful conclusion is narrower than "high impact." Science Translational Medicine belongs on a shortlist when the paper's main contribution is the translational bridge itself: a mechanistic result connected to credible human, diagnostic, therapeutic, or preventive relevance. If the paper is primarily a basic mechanism study or primarily a clinical outcome study, the citation metrics do not fix the ownership mismatch. They tell you the venue is influential; they do not tell you the manuscript is shaped for that venue.

• whether your manuscript actually fits the journal

• how likely the editor is to desk reject

• how long peer review will take

• how your specific paper will perform after publication

Those missing pieces matter more than usual in translational medicine. A paper can have beautiful mechanistic work and still miss the journal if the bridge to disease significance feels thin. A paper can have interesting patient data and still miss if the mechanistic logic feels underbuilt. The JIF does not resolve either problem.

If you are genuinely deciding whether to submit here, focus on the translational architecture of the manuscript.

• Is there a clear bridge from biological mechanism to disease relevance?

• Does the paper go beyond a promising model and show why the result matters for human health?

• Are the claims grounded in evidence that feels reviewable by both mechanistic and translational readers?

• Does the manuscript feel like a translational story from the beginning, rather than a basic paper with a thin clinical paragraph attached at the end?

That is usually a better prediction of outcome than the metric itself. The Science Translational Medicine journal profile is more useful than the raw number if you are trying to judge the editorial bar.

The most common mistake is reading 15.6 as a generic prestige label instead of a translational filter.

Some authors treat the number as proof that a strong mechanistic paper should aim here. That can be wrong if the human relevance is still too speculative. Others treat the number as lower than the giant general-medical titles and conclude the journal is more forgiving. That is also misleading. Science Translational Medicine can be less broad than those titles and still be highly selective because the paper has to satisfy a very specific translational standard.

In other words, the number helps you place the journal. It does not replace judgment about manuscript shape.

The cleanest interpretation is this:

• too high to treat as a routine backup journal

• too specialized to evaluate like a general-medical trophy target

• strongest for papers that connect mechanism, disease biology, and practical therapeutic or diagnostic relevance

If your manuscript mainly shines because of elegant basic biology, a different journal may judge it more naturally. If it mainly shines because of clinical utility without enough mechanistic depth, that can also be a mismatch. Science Translational Medicine works best when the bridge is the story.

That is the practical value of the metric page. It helps you place the journal correctly in the market, then pushes you toward the harder but more important question: does your manuscript genuinely read like translational medicine, or does it only hope to be interpreted that way?

In our pre-submission review work with translational manuscripts, we see three specific failure patterns. Our review of these manuscripts is a manuscript-fit lens, not an AAAS acceptance statistic. Through our diagnostic review, we separate the journal-level metric question from the manuscript-level evidence question. We have found that the mismatch is often visible before the journal name enters the conversation: the abstract, figures, and validation plan do not support the same reader job.

The translational claim appears only in the Discussion. The abstract and main figures establish a basic mechanism, then the final paragraphs add phrases such as "therapeutic potential" without an experiment that tests the bridge. The fix is not stronger adjectives. The study design, human-relevance evidence, and claim hierarchy need to show why translation is part of the result.

Check whether your translational claim is supported ->

Human relevance rests on one model. A mouse result can support a translational package, but a title and abstract that generalize directly to patients need a human-facing anchor: patient-derived material, a cohort signal, an organoid or primary-cell result, or another defensible bridge. The required evidence depends on the claim; there is no universal checkbox.

Check if your human-validation layer matches the claim ->

The clinical hypothesis is plausible but untested. A manuscript may identify an interesting pathway yet provide no pharmacological, genetic, diagnostic, or clinical evidence that the proposed application is feasible. That can still be strong basic science, but it may belong to a different journal owner.

Check whether STM owns your manuscript's reader job ->

The practical audit starts with three connected artifacts. The abstract should name the application without claiming more than the data show. The main figure sequence should make the mechanism-to-application bridge visible before the Discussion. The methods and supplementary material should explain how the human-facing evidence was selected, measured, and validated. When those pieces tell different stories, stronger prestige language in the cover letter usually makes the mismatch easier to see rather than easier to accept.

The review is the manuscript-level layer the JIF cannot supply. Manusights uses reviewers across 35+ current journal specialties, never trains on submitted manuscripts, and backs paid reviews with a 60-day money-back guarantee.

The former 3/195 rank and 52,583 total-citation count on this page came from an older release. The current evidence ledger records 18/207 for the selected category row and 58,152 total cites. Multi-category placement can produce more than one valid category rank, so formal use should include the category name rather than presenting one denominator as a universal journal rank.

This matrix is an editorial-fit interpretation, not a claim about what AAAS accepts or rejects at a specific rate. The current public AAAS pages reviewed for this update do not foreground an official acceptance percentage, so the page deliberately avoids third-party estimates.

The ISSN is the cleanest title-record key. Recent DOI records provide a second identity check that the abbreviation Sci Transl Med and the scitranslmed DOI prefix refer to this AAAS journal. These examples are not a ranking signal and do not substitute for JCR metrics.

Last verified: July 10, 2026.